A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole

Am J Addict. 2014 Sep-Oct;23(5):475-7. doi: 10.1111/j.1521-0391.2014.12133.x. Epub 2014 Mar 15.

Abstract

Background: Buprenorphine, used for treating opioid dependence, may have a withdrawal syndrome requiring treatment. Modulation of the dopamine system, which has been implicated in opioid withdrawal, may be a target for withdrawal for opioids such as buprenorphine.

Case report: A case is reported of a buprenorphine withdrawal syndrome with predominant symptoms of restlessness that were resistant to clonidine and benzodiazepines. It was successfully treated with the dopamine agonist pramipexole.

Scientific significance: Dopamine receptor agonists may have a place in the treatment of restlessness associated with opioid withdrawal and may have value for the broader spectrum of opioid withdrawal symptoms.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Akathisia, Drug-Induced / drug therapy
  • Benzothiazoles / therapeutic use*
  • Buprenorphine / adverse effects*
  • Dopamine Agonists / therapeutic use*
  • Humans
  • Male
  • Pramipexole
  • Psychomotor Agitation / drug therapy*
  • Substance Withdrawal Syndrome / drug therapy*

Substances

  • Benzothiazoles
  • Dopamine Agonists
  • Buprenorphine
  • Pramipexole